[Stimulatory effects of angiotensin II on angiogenesis].
Sugawara
Akira
A
Department of Comprehensive Medicine, Tohoku University Hospital.
Ito
Sadayoshi
S
D000804:Angiotensin II / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic; D013777:Tetrazoles / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D042461:Vascular Endothelial Growth Factor A; D000804:Angiotensin II; C081643:candesartan